DNLI
Denali Therapeutics Inc.
There isn't enough reported data to score DNLI yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DNLI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
DNLI's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DNLI PE Valuation
DNLI has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DNLI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DNLI's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DNLI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.73 | +$1.18 |
| Q2 2026 | -$2.84 | -$0.04 |
| Q1 2026 | -$2.88 | -$0.21 |
| Q4 2025 | -$2.97 | -$0.40 |
| Q3 2025 | -$2.91 | -$0.17 |
| Q2 2025 | -$2.80 | +$0.03 |
| Q1 2025 | -$2.67 | -$1.73 |
| Q4 2024 | -$2.57 | -$1.51 |
DNLI lost $1.73 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DNLI on earnings quality, reporting a profit while its opponent remains loss making.
DNLI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2023 | $1.3M | -64% |
| Q2 2023 | $294.1M | +460% |
| Q1 2023 | $35.1M | -17% |
| Q4 2022 | $10.3M | -18% |
| Q3 2022 | $3.6M | -33% |
| Q2 2022 | $52.5M | +129% |
| Q1 2022 | $42.1M | +432% |
| Q4 2021 | $12.5M | -96% |
DNLI's revenue is growing: $18M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -713% | N/A |
| Q2 2026 | -3622% | N/A |
| Q3 2023 | -8981% | -5961 points |
| Q2 2023 | 58% | +175 points |
| Q1 2023 | -344% | -186 points |
| Q4 2022 | -1024% | -408 points |
| Q3 2022 | -3020% | -1401 points |
| Q2 2022 | -117% | +153 points |
DNLI's operating margin was −713% last quarter, down 369 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DNLI on profitability, with a higher operating margin.
DNLI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$118.5M | -$12.5M |
| Q2 2026 | -$97.8M | -$18.2M |
| Q1 2026 | -$133.7M | +$2.9M |
| Q4 2025 | -$100.1M | -$11.3M |
| Q3 2025 | -$105.9M | -$42.9M |
| Q2 2025 | -$79.6M | +$16.4M |
| Q1 2025 | -$136.5M | -$20.8M |
| Q4 2024 | -$88.8M | +$12.1M |
DNLI has burned cash in almost every quarter: −$450M over the past year, against −$411M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DNLI on cash generation, producing positive trailing cash flow while its opponent burns cash.
DNLI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +4.8M shares |
| 1 year | +11% | +19.7M shares |
| 3 years | +40% | +54.4M shares |
| 5 years | +58% | +70.3M shares |
| Available history | +100% | +96M shares |
DNLI has 192M diluted shares, up 11% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DNLI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DNLI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -11.6x | Net Cash |
| Q2 2021 | -8.2x | Net Cash |
| Q1 2021 | -7.3x | Net Cash |
| Q4 2020 | -7.1x | Net Cash |
DNLI has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DNLI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.5 | Neutral |
| Stochastic | 23.4 | Neutral |
DNLI's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DNLI PE vs Healthcare Sector
| Metric | DNLI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DNLI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DNLI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.2 | 1.7% below |
| 20 week MA | $21.8 | 13% below |
| 50 week MA | $20.6 | 8.1% below |
| 100 week MA | $18.4 | 2.9% above |
| 200 week MA | $21.0 | 9.8% below |
DNLI's trend is mixed: it's above one of its five weekly moving averages, and 9.8% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DNLI on trend strength, trading above more of its moving averages.
DNLI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.3 | $85.9 | +370% |
| 2021 | $85.9 | $47.5 | -45% |
| 2022 | $47.5 | $27.9 | -41% |
| 2023 | $27.9 | $21.5 | -23% |
| 2024 | $21.5 | $20.6 | -4% |
| 2025 | $20.6 | $16.9 | -18% |
| 2026 YTD | $16.9 | $18.9 | +12% |
DNLI has finished five years in a row lower, and it's up 12% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DNLI on returns for 2026, with the stronger performance.